| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2882773 | The Annals of Thoracic Surgery | 2006 | 6 Pages |
Abstract
Aprotinin variants differentially inhibit PAR1-mediated platelet aggregation. With more understanding of the mechanisms of action of aprotinin and its derivatives, safer and more efficacious aprotinin variants may become available for clinical use.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jonathan R.S. MRCS, Dorian O. DM, Kenneth M. MD, Robert C. PhD,